Representatives from academia, industry, regulatory agencies, and patient advocacy groups
convened under the American Association for the Study of Liver Diseases (AASLD) and the …

Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …

To facilitate the achieving of the goal of" eliminating viral hepatitis as a major public health
threat by 2030" set by the World Health Organization, the Chinese Society of Hepatology …

Hepatitis B virus (HBV) infection remains a global public health problem with changing
epidemiology due to several factors including vaccination policies and migration. This …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

In the past 10 years, there has been a lot of enthusiasm surrounding the use of serum
hepatitis B surface antigen (HBsAg) quantification to predict disease activity and monitor …

Background & Aims Patients chronically infected with the hepatitis B virus rarely achieve
loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated …

Background & Aims There is currently no virological cure for chronic hepatitis B but
successful nucleos (t) ide analogue (NA) therapy can suppress hepatitis B virus (HBV) DNA …

Human hepatitis B virus (HBV) is a small enveloped DNA virus with a complex life cycle. It is
the causative agent of acute and chronic hepatitis. HBV can resist immune system …

Hepatitis B virus (HBV) is a significant global pathogen, infecting more than 240 million
people worldwide. While treatment for HBV has improved, HBV patients often require …